182 related articles for article (PubMed ID: 3570485)
21. [Pseudomonas immunoglobulin prophylaxis in patients with burn injuries].
Stuttmann R; Petrovici V; Hartert M
Infection; 1987; 15 Suppl 2():S71-5. PubMed ID: 3112025
[TBL] [Abstract][Full Text] [Related]
22. Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide.
Cryz SJ; Fürer E; Germanier R
Infect Immun; 1983 Mar; 39(3):1072-9. PubMed ID: 6404817
[TBL] [Abstract][Full Text] [Related]
23. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of distribution and drug resistance of pathogens of burn patients during 9 years].
Dou Y; Zhang Q
Zhonghua Shao Shang Za Zhi; 2018 Mar; 34(3):153-159. PubMed ID: 29609277
[No Abstract] [Full Text] [Related]
25. Oral ciprofloxacin therapy of infection caused by multiply resistant bacteria other than Pseudomonas aeruginosa.
Scully BE; Neu HC
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():179-85. PubMed ID: 3804906
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens.
Rossmann FS; Kropec A; Laverde D; Saaverda FR; Wobser D; Huebner J
Infection; 2015 Apr; 43(2):169-75. PubMed ID: 25428225
[TBL] [Abstract][Full Text] [Related]
27. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa. Treatment with intravenous immune globulin.
Holder IA; Naglich JG
Am J Med; 1984 Mar; 76(3A):161-7. PubMed ID: 6424445
[TBL] [Abstract][Full Text] [Related]
28. [Prevention with pseudomonas immune globulin in burn injury patients with inhalation trauma: does it have an effect on lung function and outcome?].
Stuttmann R; Hebebrand D; Hartert M; Spilker G; Doehn M
Klin Wochenschr; 1991; 69 Suppl 26():168-77. PubMed ID: 1813715
[TBL] [Abstract][Full Text] [Related]
29. Locally delivered antibodies combined with systemic antibiotics confer synergistic protection against antibiotic-resistant burn wound infection.
Felts AG; Grainger DW; Slunt JB
J Trauma; 2000 Nov; 49(5):873-8. PubMed ID: 11086779
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic efficacy of "nubiotics" against burn wound infection by Pseudomonas aeruginosa.
Dale RM; Schnell G; Wong JP
Antimicrob Agents Chemother; 2004 Aug; 48(8):2918-23. PubMed ID: 15273101
[TBL] [Abstract][Full Text] [Related]
31. [Use of pseudomonas immunoglobulin. Indications and results].
Werdan K; Melnitzki S; Pilz G; Reuschel-Janetschek E
Anasth Intensivther Notfallmed; 1989 Jun; 24(3):153-61. PubMed ID: 2504071
[TBL] [Abstract][Full Text] [Related]
32. Anticore endotoxin F(ab')2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis.
Dunn DL; Mach PA; Condie RM; Cerra FB
Surgery; 1984 Aug; 96(2):440-6. PubMed ID: 6379963
[TBL] [Abstract][Full Text] [Related]
33. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
[TBL] [Abstract][Full Text] [Related]
34. Bivalent flagellin immunotherapy protects mice against Pseudomonas aeruginosa infections in both acute pneumonia and burn wound models.
Ahmadi H; Behrouz B; Irajian G; Amirmozafari N; Naghavi S
Biologicals; 2017 Mar; 46():29-37. PubMed ID: 28065582
[TBL] [Abstract][Full Text] [Related]
35. A polyvalent human gamma-globulin immune to Pseudomonas aeruginosa: passive protection of mice against lethal infection.
Fisher MW
J Infect Dis; 1977 Aug; 136 Suppl():S181-5. PubMed ID: 70492
[TBL] [Abstract][Full Text] [Related]
36. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T
Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613
[TBL] [Abstract][Full Text] [Related]
37. Comparative opsonic activity of intravenous gamma globulin preparations for common bacterial pathogens.
Hill HR; Augustine NH; Shigeoka AO
Am J Med; 1984 Mar; 76(3A):61-6. PubMed ID: 6424458
[TBL] [Abstract][Full Text] [Related]
38. Use of passive immunotherapy in the treatment of experimental Pseudomonas aeruginosa infections in burns.
Neely AN; Holder IA
Antibiot Chemother (1971); 1987; 39():26-40. PubMed ID: 3118788
[No Abstract] [Full Text] [Related]
39. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
[TBL] [Abstract][Full Text] [Related]
40. Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia.
Pennington JE; Pier GB; Sadoff JC; Small GJ
Rev Infect Dis; 1986; 8 Suppl 4():S426-33. PubMed ID: 2944209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
